Visual Abstract

graphic
View largeDownload slide
Journal Section:
Novel Research Findings
Keywords:
Acute kidney injury, Lupus nephritis, Prognosis

Introduction: Acute kidney injury (AKI) is common in lupus nephritis (LN) and a risk factor for chronic kidney failure. Here, we aimed to assess the characteristics and prognosis of LN patients with AKI. Methods: AKI and AKI severity stages in LN patients were defined by the Kidney Disease Improving Global Outcomes (KDIGO) classification. Long-term renal outcomes and patient mortality between different stages of AKI were compared by Cox regression analysis. Results: Of 1272 LN patients, 225 (17.69%) had AKI and 72 (5.66%) were AKI stage 3. Compared with the non-AKI group, the proportion of male patients was significantly higher in the AKI group (p = 0.002). In addition, there were markedly higher proportions of hematologic system damage, more severe renal manifestations, and higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores in the AKI group than in the non-AKI group. The active and chronic lesions in renal biopsy were significantly higher in LN patients with AKI than those without AKI. During a median follow-up of 53 months, Kaplan-Meier curve showed that LN patients with AKI stage 3 had significantly poorer long-term renal outcomes (p = 0.002) and patient survival (p < 0.001) than those without AKI. Furthermore, AKI stage 3, but not stage 1 or 2 was significantly associated with adverse renal outcomes (hazard ratio [HR] = 2.52, 95% confidence interval [CI] 1.01–6.28, p = 0.048) and all-cause mortality (HR = 2.80, 95% CI: 1.18–6.61, p = 0.019) in LN patients. In patients with AKI, increased baseline serum creatinine and severe glomerular sclerosis were independent risk factors for worse renal outcomes, while higher blood pressure, increased baseline serum creatinine, and anti-Sjogren’s syndrome A positivity could indicate poor survival. Discussion: LN patients with AKI stage 3, but not stages 1 and 2, have poorer long-term renal outcomes and patient survival. Our study demonstrates the importance of early identification and management of AKI in LN patients.

Journal Section:
Novel Research Findings
Keywords:
Acute kidney injury, Lupus nephritis, Prognosis
1.
Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7.
https://doi.org/10.1038/s41572-019-0141-9
2.
Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol. 2010;21(2):345–52.
https://doi.org/10.1681/ASN.2009060636
3.
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58–66.
https://doi.org/10.1056/NEJMra1214243
4.
Ishimori S, Kaito H, Shima Y, Kamioka I, Hamahira K, Nozu K, et al. Clinicopathological characteristics and renal outcomes of childhood-onset lupus nephritis with acute kidney injury: a multicenter study. Mod Rheumatol. 2019;29(6):970–6.
https://doi.org/10.1080/14397595.2018.1532861
5.
Chen T, Zhou Y, Zhang J, Chen C, Pan J. Long-term predictive value of acute kidney injury classification in diffuse proliferative lupus nephritis with acute kidney injury. BMC Nephrol. 2020;21(1):13.
https://doi.org/10.1186/s12882-019-1676-4
6.
Zhu D, Qu Z, Tan Y, Yu F, Zhao MH. Acute kidney injury in Chinese patients with lupus nephritis: a large cohort study from a single center. Lupus. 2011;20(14):1557–65.
https://doi.org/10.1177/0961203311417035
7.
Sun F, Wang H, Zhang D, Han F, Ye S. One-year renal outcome in lupus nephritis patients with acute kidney injury: a nomogram model. Rheumatology (Oxford). 2022;61(7):2886–93.
https://doi.org/10.1093/rheumatology/keab818
8.
Chen T, Ding X, Chen B. Value of the RIFLE classification for acute kidney injury in diffuse proliferative lupus nephritis. Nephrol Dial Transpl. 2009;24(10):3115–20.
https://doi.org/10.1093/ndt/gfp235
9.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
https://doi.org/10.1002/art.1780400928
10.
Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013;61(5):649–72.
https://doi.org/10.1053/j.ajkd.2013.02.349
11.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
https://doi.org/10.7326/0003-4819-150-9-200905050-00006
12.
Jin SY, Huang DL, Dang XQ, Yi ZW. Lupus glomerulonephritis in 788 Chinese children: a multi-centre clinical and histopathological analysis based on 549 renal biopsies. Paediatr Int Child Health. 2017;37(4):286–91.
https://doi.org/10.1080/20469047.2017.1309337
13.
de Carvalho JF, do Nascimento AP, Testagrossa LA, Barros RT, Bonfá E. Male gender results in more severe lupus nephritis. Rheumatol Int. 2010;30(10):1311–5.
https://doi.org/10.1007/s00296-009-1151-9
14.
Lu H, Xiao L, Song M, Liu X, Wang F. Acute kidney injury in patients with primary nephrotic syndrome: influencing factors and coping strategies. BMC Nephrol. 2022;23(1):90.
https://doi.org/10.1186/s12882-022-02720-y
15.
Menon S. Acute kidney injury in nephrotic syndrome. Front Pediatr. 2018;6:428.
https://doi.org/10.3389/fped.2018.00428
16.
Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009;76(3):307–17.
https://doi.org/10.1038/ki.2009.136
17.
Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD, et al. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol. 2023;38(5):1653–65.
https://doi.org/10.1007/s00467-022-05775-z
18.
James MT, Bhatt M, Pannu N, Tonelli M. Long-term outcomes of acute kidney injury and strategies for improved care. Nat Rev Nephrol. 2020;16(4):193–205.
https://doi.org/10.1038/s41581-019-0247-z
19.
See EJ, Jayasinghe K, Glassford N, Bailey M, Johnson DW, Polkinghorne KR, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019;95(1):160–72.
https://doi.org/10.1016/j.kint.2018.08.036
20.
Muiru AN, Hsu JY, Zhang X, Appel LJ, Chen J, Cohen DL, et al. Risk for chronic kidney disease progression after acute kidney injury: findings from the chronic renal insufficiency cohort study. Ann Intern Med. 2023;176(7):961–8.
https://doi.org/10.7326/M22-3617
21.
McCoy IE, Hsu JY, Zhang X, Diamantidis CJ, Taliercio J, Go AS, et al. Probing the association between acute kidney injury and cardiovascular outcomes. Clin J Am Soc Nephrol. 2023;18(7):850–7.
https://doi.org/10.2215/CJN.0000000000000163
22.
Rodríguez-Almaraz E, Gutiérrez-Solís E, Rabadán E, Rodríguez P, Carmona L, Morales E, et al. Something new about prognostic factors for lupus nephritis? A systematic review. Lupus. 2021;30(14):2256–67.
https://doi.org/10.1177/09612033211061475
23.
Rijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734–43.
https://doi.org/10.2215/CJN.10601016
24.
Aktar K, Liu X, Yang X. Combination of anti-early apoptotic cell autoantibodies and anti-SSA autoantibodies in lupus nephritis. Cell Mol Biol (Noisy-le-grand). 2018;64(13):48–54.
https://doi.org/10.14715/cmb/2018.64.13.10
25.
Xue D, Shi H, Smith JD, Chen X, Noe DA, Cedervall T, et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A. 2003;100(13):7503–8.
https://doi.org/10.1073/pnas.0832411100
26.
Sun Y, Zhou C, Zhao J, Wang Q, Xu D, Zhang S, et al. Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. Lupus. 2020;29(7):795–803.
https://doi.org/10.1177/0961203320920715
27.
Bull GM, Joekes AM, Lowe KG. Renal function studies in acute tubular necrosis. Clin Sci. 1950;9(4):379–404.
28.
Basile DP. Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy. Curr Opin Nephrol Hypertens. 2004;13(1):1–7.
https://doi.org/10.1097/00041552-200401000-00001
29.
Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14(6):1549–58.
https://doi.org/10.1097/01.asn.0000064946.94590.46
30.
Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Ren Physiol. 2001;281(5):F887–99.
https://doi.org/10.1152/ajprenal.2001.281.5.F887
31.
Ratliff BB, Rabadi MM, Vasko R, Yasuda K, Goligorsky MS. Messengers without borders: mediators of systemic inflammatory response in AKI. J Am Soc Nephrol. 2013;24(4):529–36.
https://doi.org/10.1681/ASN.2012060633
32.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259–64.
https://doi.org/10.1161/01.cir.0000016043.87291.33
33.
Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003;59(3):338–43.
https://doi.org/10.1002/ccd.10534
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.